This page shows the latest lisdexamfetamine news and features for those working in and with pharma, biotech and healthcare.
top ADHD seller Vyvanse (lisdexamfetamine dimesylate) - which pulled in $2bn in sales last year, a rise of 17% and added another $563m in the first quarter.
Breaking into the adult ADHD - as well as a sideways move into binge-eating disorder with paediatric ADHD therapy Vyvanse (lisdexamfetamine) - could eventually double sales of Shire's psychiatric portfolio by
Shire recently won the first approval in the US for a medicine to help people with binge eating disorder with FDA backing for Vyvanse (lisdexamfetamine dimesylate).
Vyvanse (lisdexamfetamine dimesylate) has been used to treat attention-deficit hyperactivity disorder (ADHD) for several years and remains Shire's top-selling product; sales rose 19% to reach more than $1bn
Shire has a well-established franchise in attention-deficit hyperactivity disorder (ADHD) drugs, currently headed by Vyvanse (lisdexamfetamine dimesylate), but has latterly built up a portfolio of rare disease therapies such
The company revealed yesterday that sales of Vyvanse (lisdexamfetamine) for ADHD rose 29 per cent in the fourth quarter to $330m, more than a quarter of Shire's total revenues of
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...